Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME)
Year: 2018
Type: article
Institutions: Inserm, Université Paris Descartes, Université Pierre-et-Marie-Curie, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, Stanford Medicine, Stanford University, Dana-Farber Cancer Institute, University of Miami Health System, Sylvester Comprehensive Cancer Center, Mayo Clinic, Washington University in St. Louis
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889320258